Clinical experience in the randomized phase 3 Sierra Trial: Anti-CD45 iodine ((131)I) apamistamab [Iomab-B] conditioning enables hematopoietic cell transplantation with successful engraftment and acceptable safety in patients with active, relapsed/refractory AML not responding to targeted therapies Meeting Abstract
| Authors: | Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Koshy, N. V.; Stiff, P.; Abboud, C. Sr; Tomlinson, B.; Abhyankar, S.; Hari, P.; Al-Kadhimi, Z. S.; Chen, G. L.; Sabloff, M.; Orozco, J. J.; Foran, J. M.; Kebriaei, P.; Jamieson, K. J.; Magalhaes-Silverman, M. M.; van Besien, K.; Schuster, M. W.; Law, A.; Levy, M.; Lazarus, H. M.; Giralt, S. A.; Berger, M. S.; Spross, J. A.; Desai, A. G.; Reddy, V.; Pagel, J. M. |
| Abstract Title: | Clinical experience in the randomized phase 3 Sierra Trial: Anti-CD45 iodine ((131)I) apamistamab [Iomab-B] conditioning enables hematopoietic cell transplantation with successful engraftment and acceptable safety in patients with active, relapsed/refractory AML not responding to targeted therapies |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398807029 |
| DOI: | 10.1182/blood-2021-148497 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1791 -- Hybrid meeting, also took place online -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
